Long-term outcomes of laparoscopic aortobifemoral bypass: a retrospective cohort study www.astr.or.kr Nov. 18, 2026, 2:25 p.m.
Laparoscopic aortobifemoral bypass (LABF) represents a minimally invasive alternative to open repair for extensive aortoiliac occlusive disease, particularly TASC II C and D lesions. This retrospective study evaluated long-term outcomes in twenty patients treated at a single tertiary center between 2004 and 2012, with a median age of 65 years and 90% having TASC II D lesions. Over a ten-year follow-up period, Kaplan-Meier analysis demonstrated primary patency rates of 94.7%, 88.8%, 82.0%, and 82.0% at one, three, five, and ten years respectively, with secondary patency reaching 88% at ten years. Only one perioperative death occurred, and reintervention was required in just two patients. These findings indicate that LABF offers excellent long-term durability comparable to open repair, with minimal complications. Despite procedural challenges and steep learning curves that have historically limited adoption since its introduction in 1993, LABF provides a safe, feasible, and durable option for patients unsuitable for endovascular therapy, positioning it as a valuable surgical tool for complex aortoiliac disease management.
Drug-Coated Balloons Reshape Peripheral Artery Disease Treatment www.emjreviews.com Nov. 18, 2026, 2:25 p.m.
Drug-coated balloon angioplasty has significantly transformed the treatment of femoropopliteal artery disease, though evolving evidence reveals a nuanced safety and efficacy profile. A recent chapter review examined the development of drug-coated balloon (DCB) technology, specifically paclitaxel-coated devices, alongside emerging alternatives like sirolimus-based balloons and intravascular imaging techniques. Early paclitaxel-based balloons demonstrated substantial improvements in vessel patency and reduced repeat interventions compared to conventional plain balloon angioplasty, driving widespread adoption for superficial femoral artery interventions. However, a 2018 meta-analysis identified an unexpected mortality signal associated with paclitaxel exposure, temporarily disrupting regulatory confidence. Subsequent studies have reaffirmed the safety of paclitaxel-coated devices, yet questions persist regarding their effectiveness in advanced peripheral artery disease and chronic limb-threatening ischaemia. This distinction between device safety and treatment effectiveness remains critical when evaluating endovascular interventions. As research continues, the field is shifting toward exploring alternative antiproliferative medications and improved procedural precision, with sirolimus-based balloons representing a promising innovative direction for enhanced local drug delivery outcomes.
Deep Vein Thrombosis: Thrombectomy, Catheter-Directed Thrombolysis and Venous Stenting koruhospital.com Nov. 18, 2026, 2:24 p.m.
Deep vein thrombosis occurs when blood clots form in deep leg veins, potentially extending to the iliac and femoral vessels, causing significant swelling, pain, and long-term complications. While anticoagulant medications form the treatment foundation by preventing clot expansion and pulmonary embolism, they cannot dissolve existing clots. For carefully selected patients with extensive iliofemoral DVT, vascular surgeons and interventional radiologists employ advanced techniques including catheter-directed thrombolysis, mechanical or pharmacomechanical thrombectomy, and iliac vein stenting when underlying stenosis is identified. In rare limb-threatening cases, open surgical thrombectomy may be necessary. Treatment decisions depend on clot location, symptom duration, bleeding risk, overall health status, and the balance between potential long-term benefits and procedural risks. This comprehensive overview addresses DVT development, assessment through imaging, evidence supporting early clot removal, procedural techniques, preparation and recovery protocols, anticoagulation management, follow-up care, potential complications, and special considerations during pregnancy. Treatment planning requires evaluation by experienced vascular surgical teams specializing in venous disease.
Pharmacological strategies for hemodialysis arteriovenous fistula and graft patency: an access-stratified systematic review and network meta-analysis | European Journal of Clinical Pharmacology link.springer.com Nov. 18, 2026, 2:24 p.m.
Researchers conducted a comprehensive systematic review and network meta-analysis to evaluate pharmacological interventions aimed at improving the patency of hemodialysis arteriovenous fistulas and grafts. Published in November 2026 in the European Journal of Clinical Pharmacology, this access-stratified study examined various drug therapies designed to prevent thrombosis and maintain long-term vascular access functionality in dialysis patients. By employing network meta-analysis methodology, the researchers compared multiple pharmacological strategies across different access types, providing an evidence-based assessment of their comparative effectiveness. The findings are significant for nephrologists and dialysis practitioners, as vascular access complications remain a leading cause of morbidity and hospitalization in hemodialysis populations. This systematic review offers critical guidance for selecting optimal pharmacological approaches to enhance access survival rates, ultimately improving patient outcomes and reducing the clinical and economic burden associated with recurrent access interventions and complications in end-stage renal disease management.
Dialysis Access Declot | Articl.net articl.net Nov. 18, 2026, 2:23 p.m.
Dialysis access declot, also known as thrombectomy of arteriovenous fistula or graft, is a critical interventional radiology procedure designed to restore blood flow to thrombosed hemodialysis accesses, including native arteriovenous fistulas (AVFs) and synthetic grafts (AVGs). Prompt intervention is essential to preserve access function, maintain continuous dialysis capability, and avoid the need for temporary catheters. Multiple techniques are available to address thrombosis, with mechanical thrombectomy being particularly effective for fresh thrombus occurring within twenty-four hours or soft clot burden in native AVFs. When angioplasty results in recoil, rupture, or persistent elastic stenosis, stent grafts may be deployed. Interventional radiologists typically perform declotting procedures same-day or within twenty-four hours following hemostasis achievement. Critically, clinicians must identify and correct the underlying stenosis—most commonly venous anastomotic stenosis caused by neointimal hyperplasia—during the initial intervention to prevent thrombosis recurrence. This comprehensive approach combining clot removal with stenosis treatment significantly improves long-term access patency and reduces patient morbidity associated with hemodialysis complications.
Comparison of the short-term and long-term effects of AngioJet and AcoStream mechanical catheter thrombolysis on acute iliofemoral vein thrombosis www.elsevier.es Nov. 14, 2026, 5:24 a.m.
Clinics, the official scientific journal of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, published a comparative study evaluating two mechanical thrombectomy devices for treating acute iliofemoral deep vein thrombosis. Researchers conducted a four-year retrospective case-control study involving 243 patients who underwent endovascular interventional therapy, dividing participants into two groups based on treatment method: those treated with AngioJet mechanical thrombectomy and those receiving AcoStream thrombectomy. The study addresses a significant research gap by comprehensively evaluating both short-term and long-term clinical outcomes and safety profiles in subacute lower limb deep vein thrombosis patients. This direct comparison of AngioJet and AcoStream devices provides clinicians with evidence-based guidance for selecting appropriate thrombectomy interventions. By assessing real clinical benefits beyond immediate procedural success, the research helps optimize treatment strategies for patients with acute iliofemoral venous thrombosis, ultimately improving clinical decision-making and patient outcomes in this critical vascular disease population.
Diabetic Foot Vascular Surgery: Distal and Pedal Bypass for Limb-Threatening Ischaemia koruhospital.com Nov. 14, 2026, 5:24 a.m.
Diabetic foot vascular surgery addresses blocked arteries in diabetic patients, predominantly affecting small vessels below the knee while sparing larger thigh arteries. This vascular pattern, combined with diabetes-related nerve damage and infection susceptibility, enables minor injuries to develop into non-healing wounds. The distal bypass procedure, the characteristic intervention, creates a new blood channel using autologous vein grafts that reroute circulation around blocked segments to arteries at the ankle or foot level. Revascularization options include minimally invasive balloon angioplasty with stenting or open bypass surgery, with selection based on blockage patterns, vein quality, patient health status, and foot condition. Treatment integrates bypass surgery with wound care, infection management, and diabetes control to prevent amputation. The approach requires comprehensive assessment through imaging and examination by vascular surgeons experienced in diabetic foot management. Long-term outcomes depend on graft patency, careful monitoring, and protection of both the treated foot and contralateral limb during follow-up.
Case Study: Extensive Echogenic DVT Managed With the Liberant™ Thrombectomy System evtoday.com Nov. 14, 2026, 5:23 a.m.
A middle-aged female patient presented with acute deep vein thrombosis affecting her right leg following an upper respiratory infection, with imaging revealing extensive echogenic thrombus extending through the popliteal, femoral, common femoral, and iliac veins, accompanied by bilateral subsegmental pulmonary emboli. Initial anticoagulation with heparin proved insufficient to manage her severe symptoms, including visible edema and cyanotic discoloration. Given the extensive nature of the DVT, the patient's young age, and her continued pain, vascular surgeons elected to perform percutaneous mechanical thrombectomy using the 12-Fr Liberant thrombectomy system manufactured by Medtronic. The procedure involved accessing the below-knee popliteal vein via the Seldinger technique using Pinnacle sheaths from Terumo Interventional Systems, followed by diagnostic venography and cavography to assess thrombus burden. The case demonstrates the clinical value of mechanical thrombectomy in managing extensive acute DVT when anticoagulation alone proves inadequate, particularly in younger patients at risk for post-thrombotic syndrome and significant morbidity from conservative management alone.
AV Fistula Revision and Aneurysm Repair: Stenosis, Clotted Fistula, Steal and Recovery koruhospital.com Nov. 14, 2026, 5:23 a.m.
Arteriovenous fistula revision encompasses surgical and catheter-based procedures designed to repair dialysis fistulas that have narrowed, clotted, developed aneurysms, or caused complications in the hand, arm, or heart. For kidney failure patients, the fistula serves as a critical lifeline enabling regular hemodialysis sessions; loss of access typically necessitates temporary neck catheters and additional surgery. Over months and years, repeated high blood flow and needling cause vein wall thickening, narrowing, clot formation, ballooning segments, and potential blood steal from the hand or cardiac strain. Treatment options range from balloon angioplasty and thrombectomy for clot removal to patch repair, plication, partial graft replacement, and arterial connection repositioning. More complex cases may require flow-reducing procedures or fistula closure with new access creation elsewhere. Assessment utilizes ultrasound and fistulography imaging. Treatment selection depends on examination by cardiovascular surgeons working collaboratively with nephrologists and dialysis teams. Understanding warning signs, risks, recovery timelines, and long-term access protection strategies is essential for patients dependent on these vascular connections for survival.
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT) www.penumbrainc.com Nov. 14, 2026, 5:23 a.m.
Penumbra, Inc. announced FDA clearance for its Lightning computer assisted vacuum thrombectomy (CAVT) technology to treat deep vein thrombosis (DVT), marking the first cleared mechanical thrombectomy device for this indication. The clearance is supported by the BOLT-DVT prospective, multicenter Investigational Device Exemption trial, which demonstrated that CAVT safely and effectively removes blood clots while offering significant advantages over standard anticoagulation therapy. In the trial, 98 percent of patients achieved complete or near-complete thrombus removal with a median device time of just 18 minutes and a low 48-hour major adverse event rate of 3.1 percent. Patients experienced durable pain relief, improved quality of life, and low re-thrombosis rates. This advancement is clinically significant given that approximately 900,000 venous thromboembolism cases occur annually in the United States, with DVT potentially leading to life-threatening pulmonary embolism. The BOLT-DVT results represent the first meaningful advancement in DVT treatment standards in decades, positioning CAVT to transform the treatment algorithm and improve patient outcomes compared to decades-old anticoagulation-only approaches.
End of life care in chronic limb threatening ischemia: a retrospective cohort study eprints.whiterose.ac.uk Nov. 10, 2026, 11:32 p.m.
Chronic limb-threatening ischemia (CLTI), the end-stage of peripheral artery disease characterized by prolonged rest pain and tissue loss, carries significant mortality yet lacks substantial literature on end-of-life care approaches. A retrospective cohort study by Davies and colleagues, published in JVS-Vascular Insights in 2024, examined 186 CLTI patients who underwent surgical revascularization or amputation between 2018 and 2019. The cohort, predominantly male with median age 67.5 years, demonstrated 72% two-year survival. However, findings revealed critical gaps in palliative care delivery: only 10.8% received dedicated palliative care consultations, occurring a median of just five days before death. Among deceased patients, merely 8.1% had documented preferred place of care or death, and 18.3% had documented care priorities. This study highlights the substantial underutilization of palliative care integration in CLTI management. The research underscores the urgent need for earlier palliative care involvement, improved advance care planning discussions, and better coordination between vascular surgery and palliative medicine to optimize patient outcomes and quality of life in this high-mortality condition.
A concise systematic review: Implantation of the small-diameter tissue-engineered vascular graft in human studies hvt-journal.com Nov. 10, 2026, 11:32 p.m.
This systematic review evaluates tissue-engineered vascular grafts (TEVGs) for two critical clinical applications. In hemodialysis access, three studies examined small-diameter TEVGs as arteriovenous conduits for end-stage renal disease patients. Lawson et al. tested an allogeneic bioengineered human acellular vessel in 59 patients as brachial-to-axillary grafts, achieving 70% primary patency at six months in the US cohort with minimal complications and no immunologic rejection. Wystrychowski et al. reported similar results with an endothelialized tissue-engineered graft derived from human dermal fibroblasts, achieving 75% patency at 12 months. Harlander-Locke et al. evaluated the xenogeneic bovine carotid artery graft (Artegraft) in poor fistula candidates, reporting 60.5% patency at one year versus 10.1% for standard ePTFE. For peripheral arterial disease bypass, Williams et al. used point-of-care sodded ePTFE grafts with adipose-derived cells achieving 60% patency at 12 months, while Gutowski et al. implanted allogeneic bioengineered vessels as femoropopliteal bypasses with 58% patency at 24 months. Overall, TEVGs demonstrated promising clinical performance with manageable complication profiles across both indications.
Vantis Vascular’s 6-F CrossFast System Receives FDA Clearance evtoday.com Nov. 10, 2026, 10:58 p.m.
Vantis Vascular announced FDA 510(k) clearance on October 14, 2026, for a new 6-F model of its CrossFast integrated microcatheter advanced delivery system, launching commercially in November. The CrossFast system is designed to work with guide catheters to access coronary and peripheral vasculature regions while facilitating placement of interventional devices. Complementing the existing 5.5-F model, the 6-F CrossFast addresses procedural flexibility needs for navigating complex anatomies. The larger lumen and shorter distal tip accommodate a broader range of interventional technologies used in complex percutaneous coronary intervention procedures, notably intravascular ultrasound and intravascular lithotripsy. Dr. Jasvindar Singh, an interventional cardiologist at Washington University and Barnes-Jewish Hospital, highlighted that the expanded lumen capacity enables IVUS integration—increasingly critical in complex PCI cases—and supports additional interventional technologies, substantially broadening clinical applications for challenging procedures.
SIRONA 3-Year Results: Sirolimus-Coated Balloon Shows Higher Freedom From Repeat Revascularization Than Paclitaxel-Coated Balloons in Femoropopliteal Disease finance.yahoo.com Nov. 10, 2026, 10:56 p.m.
Three-year results from the SIRONA trial, presented at TCT 2026 and published in JACC: Cardiovascular Interventions, demonstrate superior durability of sirolimus-coated balloon angioplasty compared to paclitaxel-coated balloons for femoropopliteal artery disease. The randomized, multicenter trial enrolled 482 patients across 25 centers in Germany and Austria, comparing Concept Medical's MagicTouch PTA sirolimus-coated balloon to paclitaxel alternatives. At three years, freedom from clinically driven target lesion revascularization reached 88.2% with sirolimus versus 80.2% with paclitaxel, representing an 8.0 percentage point absolute difference. Both treatments demonstrated equivalent walking capacity, quality of life improvements, and safety profiles. Major adverse events were rare in both groups, with 7.4% all-cause mortality and amputation-free survival exceeding 92% in each arm. This represents the first randomized trial comparing these technologies beyond two years. The findings gain significance amid recent concerns about paclitaxel-coated devices following the SWEDEPAD 2 trial, which prompted the European Society for Vascular Surgery to recommend cautious use in claudication patients.
Sirolimus-Eluting Balloon Achieves 91.1% One-Year Freedom From Revascularization in Real-World Study bioengineer.org Nov. 10, 2026, 10:56 p.m.
An international prospective real-world registry designated the SUCCESS PTA study evaluated sirolimus-eluting balloon angioplasty for treating peripheral arterial disease across diverse clinical settings. The investigation examined hundreds of patients with intermittent claudication and chronic limb-threatening ischemia, demonstrating that localized sirolimus delivery through specialized sustained-release micro-reservoirs achieved 91.1 percent freedom from clinically driven target lesion revascularization at one-year follow-up across various lower extremity vascular beds. These results matched historical benchmarks established by paclitaxel-coated balloons, suggesting limus-based formulations provide a viable endovascular alternative for complex peripheral vascular pathology. This finding is particularly significant given that prior randomized trials, including SWEDEPAD 1 and SWEDEPAD 2, revealed that paclitaxel-eluting devices failed to improve quality of life in claudication patients or reduce amputation rates in chronic limb-threatening ischemia cohorts. Pharmacologically, sirolimus operates as a cytostatic agent, reversibly halting cellular proliferation while producing localized anti-inflammatory effects within treated arterial structures, overcoming previous biophysical delivery challenges that hindered its use compared to paclitaxel.
Wayne’s Teleflex Receives FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold biobuzz.io Nov. 10, 2026, 10:56 p.m.
Teleflex, a Pennsylvania-based medical device company, announced on October 22, 2026, that the FDA granted Breakthrough Device Designation (BDD) to its Freesolve™ Resorbable Magnesium Scaffold (RMS) for percutaneous coronary intervention, a minimally invasive procedure treating narrowed heart arteries. The designation accelerates FDA review for devices addressing life-threatening conditions with unmet clinical needs and superior treatment potential. Freesolve™ RMS, also known clinically as DREAMS 3G RMS, comprises Teleflex's BIOmag™ Magnesium Alloy coated with BIOlute™ Bioabsorbable Coating. The scaffold supports arterial walls during and after procedures, then dissolves completely, with 99% absorption within 12 months. This is the platform's second BDD; the FDA previously designated Freesolve™ Below-The-Knee RMS for chronic limb-threatening ischemia in 2024. The designation represents significant progress toward commercialization, though regulatory approval remains pending. The resorbable scaffold technology offers physicians a "leave-nothing-behind" alternative, potentially reducing dependence on permanent implants and addressing an important clinical gap in coronary intervention.
Comparative outcomes of endovascular versus synthetic bypass for isolated superficial femoral artery lesions: A 3-year single-center cohort study journals.plos.org Nov. 10, 2026, 10:55 p.m.
Peripheral artery disease affects millions globally, ranging from intermittent claudication to critical limb-threatening ischemia. This three-year single-center cohort study compared two treatment approaches for isolated superficial femoral artery lesions: percutaneous transluminal angioplasty with stenting (PTAS) and synthetic graft femoropopliteal bypass (FPB). Researchers retrospectively analyzed 88 patients with no prior vascular interventions between 2016 and 2020, with 29 receiving PTAS and 59 undergoing FPB. Over three years, primary outcomes including reintervention rates, limb amputation, mortality, and vessel patency showed no statistically significant differences between treatments. The hazard ratio for loss of primary patency in FPB versus PTAS was 1.89, though this was not statistically significant. Notably, subgroup analysis of TransAtlantic Inter-Society Consensus grade B and C lesions—which lack standardized treatment protocols—similarly revealed no significant differences in patency outcomes. However, the study's limited sample size and low statistical power suggest findings should be considered hypothesis-generating rather than definitive, with clinically meaningful differences remaining possible.
Late-Breaking Clinical Trial Results Announced at VIVA 2026 www.google.com Nov. 7, 2026, 5:26 a.m.
At VIVA 2026 in Las Vegas, the VIVA Foundation presented late-breaking clinical trial results advancing peripheral vascular disease treatment. The SELUTION4SFA trial compared the SELUTION SLR drug-eluting balloon (DEB) to standard balloon angioplasty (PTA) for treating superficial femoral and proximal popliteal artery lesions in symptomatic peripheral artery disease patients. This prospective, multicenter, randomized controlled study enrolled 300 subjects across 34 clinical sites in the United States, Europe, and Asia, with 205 patients receiving the SELUTION SLR DEB and 95 receiving conventional PTA. The trial demonstrated that SELUTION SLR DEB achieved superior efficacy at 12 months with 78.6% primary patency compared to 65.2% for PTA (p=0.019), and met non-inferiority safety endpoints with 92.8% versus 84.2% (p<0.0001). Kaplan-Meier estimates showed 90.3% primary patency and 94.6% freedom from clinically-driven target lesion revascularization for DEB versus 79.4% and 85.3% for PTA respectively. These results underscore the clinical significance of drug-eluting balloon technology in improving outcomes for peripheral artery disease patients.
Serration Remodeling Therapy for Peripheral Artery Disease | Robert Miraglia posted on the topic www.google.com Nov. 7, 2026, 5:25 a.m.
Serration Remodeling Therapy (SRT) addresses critical challenges in treating peripheral artery disease affecting the feet, particularly in complex cases. A case presentation in Endovascular Today by Dr. Melissa Keller, PhD, demonstrates SRT's clinical application in a diabetic patient with critical limb-threatening ischemia (CLTI) and severe pedal artery disease complicated by a non-healing wound. SRT provides controlled vessel expansion in small, calcified vessels while eliminating typical complications such as elastic recoil and residual waist formation. This technique represents a significant advancement for limb salvage interventions, offering predictable luminal expansion outcomes where conventional endovascular approaches face limitations. The innovation highlights the importance of understanding emerging evidence, clinical expertise, and market developments in peripheral vascular intervention, particularly for addressing the challenging anatomy of pedal arteries in diabetic patients requiring wound healing and tissue preservation.
Therapeutic decoupling of restenosis prevention from impaired vascular healing with regenerative nanovesicle-eluting bioresorbable scaffolds www.google.com Nov. 7, 2026, 5:25 a.m.
Researchers addressing a critical limitation in stent-based cardiovascular treatment have developed a novel therapeutic approach that decouples restenosis prevention from vascular healing complications. Traditional drug-eluting stents reduce neointimal hyperplasia by suppressing vascular smooth muscle cell proliferation, but this cytostatic mechanism delays re-endothelialization and impairs vascular repair. An international collaboration involving institutions including Asan Medical Center, Chung-Ang University, McGill University, and Ajou University proposes an innovative regenerative scaffold strategy designed to maintain antirestenotic efficacy while promoting healthy vascular healing. Published in Theranostics in January 2027, this research addresses a fundamental therapeutic tradeoff that has limited stent-based revascularization effectiveness. By employing a regenerative scaffold approach rather than relying solely on cytostatic drug delivery, the study aims to achieve both restenosis prevention and optimal vascular repair simultaneously. This advancement has significant implications for improving long-term outcomes in interventional cardiology and reducing restenosis-related complications that currently necessitate repeat revascularization procedures in many patients.